A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting
Latest Information Update: 09 Nov 2023
At a glance
- Drugs Anastrozole (Primary) ; Trastuzumab-deruxtecan (Primary)
- Indications Carcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms TRIO-US B-12 TALENT
- 10 Dec 2022 Originally 6cycles (cy) were given but in 02/2022, an amendment increased the number of treatment cyfrom 6 to 8 for newly enrolled pts, or those who had not yet had surgery.
- 10 Dec 2022 Results(n=58; from stage 1 of the trial) assessing the safety of Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer presented at the 45th Annual San Antonio Breast Cancer Symposium
- 21 Nov 2022 According to a Daiichi Sankyo Company media release, data from the trial will be presented at the 2022 San Antonio Breast Cancer Symposium (#SABCS22).